Video

Visus CEO updates on lead product candidate, 2021 pipeline

Author(s):

OT Staff Reports
Conferences|AAO

Visus Therapeutics CEO Ben Bergo shares an update on the status of its lead product candidate for presbyopia treatment as well as what's in the company's pipeline for 2021.


See more AAO coverage here

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Jason Bacharach, MD, on early-onset efficacy with perfluorohexyloctane in dry eye
CIME 2025: Neda Shamie, MD, on expanding options in pharmacological presbyopia management
Related Content
(Image credit: AdobeStock/peshkova)
May 17th 2025

Q&A: Joaquin De Rojas, MD, on ASCRS 2025 Best Paper of Session for advancing AK with machine learning

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

AAVantgarde Bio presents positive data for retinitis pigmentosa and Stargardt disease therapies
May 16th 2025

AAVantgarde Bio presents positive data for retinitis pigmentosa and Stargardt disease therapies

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Q&A: Christine Kay, MD, gives an investigator's perspective on the PRISM clinical trial
May 15th 2025

Q&A: Christine Kay, MD, gives an investigator's perspective on the PRISM clinical trial

Positive preclinical data on melanocortin agonists for retinopathy
May 15th 2025

Positive preclinical data on melanocortin agonists for retinopathy

© 2025 MJH Life Sciences

All rights reserved.